Cat. No.: DIA-0231016
Product Information | |
---|---|
CAS No. | 1195768-06-9 |
Synonyms | GSK2118436 Mesylate |
Formula | C24H24F3N5O5S3 |
Molecular Weight | 615.67 |
SMILES | CC(C)(C)C1=NC(=C(S1)C2=CC=NC(=N2)N)C3=C(F)C(=CC=C3)N[S](=O)(=O)C4=C(F)C=CC=C4F.C[S](O)(=O)=O |
Product Description | Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with IC50s of 0.8 nM, 3.2 nM and 5 nM for B-Raf (V600E), B-Raf (WT) and C-Raf, respectively. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.